Precision medicine taking the individual’s whole genome into consideration
Precision medicine has the potential to transform drug therapy and patients’ lives. A recent study published in Human Genomics brings us closer to unlocking… Read more »
Magnus Ingelman-Sundberg & Volker Lauschke
Magnus Ingelman-Sundberg, PhD; BSc.Med is Professor of Molecular Toxicology since 1996 and research group leader in Pharmacogenetics at the Department of Physiology and Pharmacology, Karolinska Institutet since 2006. His research focuses on genetics, epigenetics, polymorphism, regulation, function and toxicology of the hepatic ADME system with aims at understanding interindividual differences in drug response. For further info from an Interview with Magnus see: Trends Pharmacol Sci. 2015; 36:65-7.
Volker Lauschke obtained his PhD degree from the EMBL and the University of Heidelberg, Germany, in 2013. In 2014 he moved to Karolinska Institutet, Sweden, as a Marie Curie Fellow and since January 2017 heads the research group of Liver Function and Drug Development. Volker is a member of the Swedish Strategic Research Program in Diabetes and the Ubiquitous Pharmacogenomics Consortium, as well as member of the Editorial Boards of Human Genomics and Frontiers in Pharmacology.
Volker Lauschke obtained his PhD degree from the EMBL and the University of Heidelberg, Germany, in 2013. In 2014 he moved to Karolinska Institutet, Sweden, as a Marie Curie Fellow and since January 2017 heads the research group of Liver Function and Drug Development. Volker is a member of the Swedish Strategic Research Program in Diabetes and the Ubiquitous Pharmacogenomics Consortium, as well as member of the Editorial Boards of Human Genomics and Frontiers in Pharmacology.
Latest posts by Magnus Ingelman-Sundberg & Volker Lauschke (see all)